{
  "id": 11707210,
  "title": "Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026",
  "url": "https://urgent.news/2026/10/03/agenus-reports-48-estimated-three-year-survival-with-bot-bal-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-03T14:51:20.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/agenus-reports-48-estimated-three-year-survival-with-botbal-in-recurrent-ovarian-cancer-at-igcs-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Survival estimate remained at 48% between years two and three, extending evidence of durable benefit Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer LEXINGTON, Mass. — Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}